

Hiroaki Ikeda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6229715/publications.pdf>

Version: 2024-02-01

15
papers

5,369
citations

759233

12
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

8494
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer immunoediting: from immunosurveillance to tumor escape. <i>Nature Immunology</i> , 2002, 3, 991-998.	14.5	4,290
2	Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy. <i>Immunity</i> , 2000, 13, 265-276.	14.3	315
3	Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR. <i>Cancer Research</i> , 2009, 69, 9003-9011.	0.9	174
4	Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2268-2277.	7.0	139
5	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 1278-1294.	8.2	102
6	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. <i>Journal of Translational Medicine</i> , 2013, 11, 246.	4.4	94
7	Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8 ⁺ T cells. <i>European Journal of Immunology</i> , 2009, 39, 241-253.	2.9	50
8	Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. <i>Vaccine</i> , 2009, 27, 6854-6861.	3.8	45
9	T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. <i>International Immunology</i> , 2016, 28, 349-353.	4.0	45
10	Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8 ⁺ T cells with tumor regression. <i>Cancer Science</i> , 2009, 100, 1317-1325.	3.9	34
11	NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. , 2022, 10, e003811.		26
12	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 663-675.	4.2	22
13	CD4 + T cells support polyfunctionality of cytotoxic CD8 + T cells with memory potential in immunological control of tumor. <i>Cancer Science</i> , 2020, 111, 1958-1968.	3.9	19
14	Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. <i>Immunotherapy</i> , 2016, 8, 527-540.	2.0	10
15	Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors. , 2022, 10, e003958.		4